The oncgnostics team
We at oncgnostics are specialized in the development of in vitro diagnostic tests for all areas of cancer diagnostics.
Our tests are based on epigenetic changes, so called DNA methylations which are characteristic for cancer cells. These highly informative biomarkers, validated and patented by us, represent the core of our products and provide the basis for our activities.
Our business strategy aims in the IVD test development field at, after test validation and initial preclinical trials, cooperation with international partners. After registration, products will be marketed directly or through licensing to cooperation or distribution partners.
contact: contact[at]oncgnostics.com
oncgnostics – awards and distinctions
| 2022 | oncgnostics GmbH was named one of Germany’s most innovative companies by the business magazine Capital |
| 2019 | Company of the Year 2019 – Reader’s prize of the Ostthüringer Zeitung |
| 2017 | Thuringian Innovation Prize in the category light & life |
| 2017 | IQ innovation prize Mitteldeutschland for the cluster Life Science |
| 2015 | European Venture Summit 2015 – award winner |
| 2014 | Thuringian Innovation Prize: award for young companies |
| 2014 | Thuringian Innovation Prize: nomination in the category light & life |
| 2013 | Thuringian Research Prize to the oncgnostics founders |
| 2013 | Thuringian Elevator Pitch: 2nd place companies |
| 2012 | Science4Life business plan contest: top 10 |
| 2011 | Founder contest Startbahn Ruhr Medical Industry: 1st prize |
| 2011 | Thuringian Founder Prize: winner young companies |
| 2011 | Thuringian Elevator Pitch: winner young companies and projects |
Presentation of our company for the Thuringian Innovation Prize: award for young companies: (german)
© audiovisual elements
An informative film about GynTect, nominated for the Thuringian Innovation Prize in the category light & life: (german)
© audiovisual elements